Maxygen

This page is no longer active*** Maxygen Inc. was a biopharmaceutical company focused on developing improved versions of protein drugs through internal development and external collaborations and other arrangements. They used the MolecularBreedingTM directed evolution technology platform, along with ancillary technologies, and extensive protein modification expertise to pursue the creation of biosuperior proteins. Maxygen Inc. was dissolved in 2013. Visit the active Maxygen page at linkedin.com/company/maxygenllc

Maxygen operates in the Biotechnology industry.

Maxygen's revenue is $55.50m

Maxygen has 51 - 200 employees.